Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
30 employees
Ampersand Biomedicines: Innovating disease-targeted programming therapeutics via our AND™ Platform.
HQ
Founded
2020
Founded by Flagship Pioneering, Ampersand Biomedicines is dedicated to revolutionizing drug development through its Address, Navigate, Design (AND)™ Platform. The company's core mission is to create novel programming therapeutics that act precisely at the site of disease, enhancing efficacy while maintaining safety and tolerability. Ampersand focuses on developing these targeted therapies to overcome the traditional challenges of affecting healthy tissues or cells, aiming to significantly improve patient outcomes.
Notable affiliated individuals include the team at Flagship Pioneering, a well-regarded venture capital firm known for incubating transformative biotech companies. Ampersand Biomedicines has achieved significant milestones in its early stages, particularly in advancing its AND™ Platform. The company's innovative approach has the potential to make a substantial impact on the biomedicine field by offering more precise and safer treatment options for various diseases.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Therapeutics
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Ampersand Biomedicines founded?
Ampersand Biomedicines was founded in 2020.
Where is Ampersand Biomedicines's headquarters located?
Ampersand Biomedicines's headquarters is located in Boston, MA, US.
When was Ampersand Biomedicines's last funding round?
Ampersand Biomedicines's most recent funding round was for $50M (USD) in March 2023.
How many employees does Ampersand Biomedicines have?
Ampersand Biomedicines has 30 employees as of Feb 4, 2024.
How much has Ampersand Biomedicines raised to-date?
As of July 05, 2023, Ampersand Biomedicines has raised a total of $50M (USD) since Mar 7, 2023.
Add Comparison
Total Raised to Date
$50M
USD
Last Update Mar 7, 2023
Last Deal Details
$50M
USD
Mar 7, 2023
Series Unknown
Current Employees
30
Last updated: Feb 4, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts